The U.S. Food and Drug Administration approved Eli Lilly’s Verzenio (abemaciclib) for a specific type of early breast cancer that is at high risk of recurrence after surgery.
Pfizer’s Phase III study assessing Ibrance as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant chemotherapy failed to meet the clinical trial’s primary endpoint.
ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.
Eli Lilly’s drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial.
Special Feature – First Year After Launch: The specialties win againAnkylosing Spondylitits, Antipsychotics, August 2017, Autoimmune Diseases, Biotech, Blockbusters, Breast Cancer, CDK 4/6 Inhibitors, First Year After Launch special feature, First-In-Class, Hepatitis C, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, New Drug Applicationa, New Molecular Entities, Plaque Psoriasis, Potential Blockbusters, Product Launches, Psoriatic Arthritis, Specialty Medicines, Therapeutics
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
Med Ad News asked Adrienne Morgan and Geetiksa Prasad, the account and copy leads for Ibrance at H4B Chelsea, about their agency’s work with Pfizer’s star breast cancer brand.
Pfizer won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market.